Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable

NCT ID NCT06192797

Recruiting now ⭐️ CURE ⭐️ Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of three treatments can shrink inoperable intrahepatic cholangiocarcinoma (a type of bile duct cancer) enough to allow surgical removal. The approach delivers chemotherapy directly into the liver's blood supply (HAIC) along with the targeted drug lenvatinib and the immunotherapy pucotenlimab. The main goal is to see how many patients become eligible for curative surgery, with secondary measures including tumor shrinkage and safety. The study enrolls 36 adults whose tumors cannot be fully removed by standard surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of hepatic artery infusion chemotherapy (GEMOX), lenvatinib, and pucotenlimab
What this could lead to
If successful, this approach could turn inoperable bile duct cancers into surgically removable ones, potentially offering a path to a cure.
What could go wrong
This is an early-phase, single-arm trial with only 36 participants, so results may not apply broadly. The combination therapy carries risks of liver damage, bleeding, and immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA NON-RESECTABLE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.